Overview
- 8 public-safe observations are available for this inspection.
- 2 structured CFR citations are represented.
- 1 investigator is tied to this Form 483.
Inspectional observations
Each observation cites the regulation FDA found the firm out of compliance with.
3 Apr 2019
21 CFR 111.70(b)(2)
Specifications-component purity, strength, composition
Cited by Elodie X Tong-Lin
3 Apr 2019
21 CFR 111.70(b)(2)
Specifications-component purity, strength, composition
Cited by Elodie X Tong-Lin
3 Apr 2019
21 CFR 111.70(b)(2)
Specifications-component purity, strength, composition
Cited by Elodie X Tong-Lin
Inspected site
AGAyanda GmbHPritzwalk, Germany
Inspection team
Cited regulations
CFR citations associated with this Form 483.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 111.70(b)(2) | Cited across public-safe Form 483 observations | 4x |
| 21 CFR 111.75(a)(2)(ii)(D) | Cited across public-safe Form 483 observations | 4x |
Full 483 report
Get the verbatim text of all 8 observations
Every observation in full, so your team sees exactly what was cited and how it was answered.
- The site's full inspection history around this Form 483
- Whether these citations escalated to a warning letter
- The investigators involved and the citations they repeat elsewhere